Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Repeated exclusive enteral nutrition in the treatment of pediatric Crohn's disease

This month's Alimentary Pharmacology & Therapeutics identifies predictors of efficacy and outcome of repeated exclusive enteral nutrition in the treatment of pediatric Crohn's disease.

News image

Exclusive enteral nutrition induces remission and mucosal healing in children with active Crohn's disease.

Dr Schwerd and colleagues from Germany compared short- and long-term outcomes of the first vs second courses of exclusive enteral nutrition, and identified predictors of sustained remission.

The researchers performed a retrospective single center analysis of all patients with Crohn's disease treated with exclusive enteral nutrition over 7.5 years.

Patients were excluded if exposed to anti-TNFα or corticosteroids 3 months prior to exclusive enteral nutrition.

Data included disease phenotype, activity, NOD2 genotype, laboratory indices and anthropometrics.

The team defined remission and relapse by mathematically weighted Paediatric Crohn's Disease Activity Index (wPCDAI) with 1-year follow-up.

Fecal calprotectin more than 200 μg/g during enteral nutrition was associated with shorter remission
Alimentary Pharmacology & Therapeutics

Of 94 patients treated with exclusive enteral nutrition, 52 fulfilled inclusion criteria.

The research team reported that azathioprine was started within the first month in 33/52 patients.

The researchers noted that 26/52 received a second exclusive enteral nutrition course.

First compared to second exclusive enteral nutrition revealed higher wPCDAI at start, tended to higher remission rates after 3 months, but showed comparable 1-year relapse rates.

The team noted that disease activity, weight gain and inflammatory markers showed better improvement with first exclusive enteral nutrition.

Fecal calprotectin more than 200 μg/g during exclusive enteral nutrition was associated with shorter remission.

The research team observed that certain NOD2 genotypes were related to higher relapse rates.

Dr Schwerd's team concludes, "Exclusive enteral nutrition induces remission in active Crohn's disease, but efficacy tends to decrease with the second course."

"Despite early azathioprine use, 1-year relapse rates are high, but may be related to NOD2 genotype."

Aliment Pharmacol Ther 2014: 39(12): 1398–1407
03 June 2014

Go to top of page Email this page Email this page to a colleague

 26 February 2015

Advanced search
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Questionnaires for GERD
 26 February 2015 
Herbal products and the liver
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patients’ colonoscopist selection
 11 February 2015 
NAFLD and CVD
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis
 02 February 2015 
Colonoscopy and colon cancer risk in IBD
 02 February 2015 
Sirolimus in Hep C virus infected liver graft recipients
 02 February 2015 
Treatment of C. diff in adults
 30 January 2015 
Removal of rectal neoplasms
 30 January 2015 
HIV-associated NAFLD and primary NAFLD
 30 January 2015 
Narcotic use in children with IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us